Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Schnell O
Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas
European Association of NeuroOncology Magazine 2014; 4 (3): 109-115

PDF    Summary    Overview   

This Image - Fig. 1: MGMT Fig. 2: Glioblastoma
Figure/Graphic 1: MGMT
Effect of MGMT promoter methylation status in glioblastomas. In GBM, hypermethylation of the MGMT promoter results in reduction of MGMT protein, which in turn leads to improved chemosensitivity for TMZ chemotherapy or combined radiochemotherapy. Therefore, MGMT promoter methylation is correlated with improved overall survival in these patients. In contrast, GBM patients with unmethylated MGMT promoter status may have reduced response to radio-/chemotherapy and therefore worse prognosis (mod from [1, 17]).
 
MGMT
Previous ImageNext Image   


Figure/Graphic 1: MGMT
Effect of MGMT promoter methylation status in glioblastomas. In GBM, hypermethylation of the MGMT promoter results in reduction of MGMT protein, which in turn leads to improved chemosensitivity for TMZ chemotherapy or combined radiochemotherapy. Therefore, MGMT promoter methylation is correlated with improved overall survival in these patients. In contrast, GBM patients with unmethylated MGMT promoter status may have reduced response to radio-/chemotherapy and therefore worse prognosis (mod from [1, 17]).
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum